Faculty profile

Catalin Mihalcioiu

ResearcherMedicineMcGill University

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a McGill University directory, so their courses and email address may be missing. Find their university profile.

Catalin Mihalcioiu

Researcher

Medicine

Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
14 publications in the last five years, latest in 2026.
Principal investigator on 2 research grants (2 CIHR), most recently in 2022.
Supervised 1 trainee who won CIHR awards, most recently in 2012.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Biomarkers Cancer Targeted Therapy Humanized Monoclonal Antibodies Ind Enabling Studies Parathyroid Hormone-Related Protein Affinity-Based Purification Antibody Breast Cancer

Latest papers

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.
JCO oncology practice · 2026
Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer.
Microbiome · 2026
Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.
Nature medicine · 2026

All 31 publications

Latest funding

Fecal microbiota transplantation in combination with immune checkpoint blockade in patients with advanced melanoma: A randomized phase II trial
CIHR · 2023 · Co-investigator
$1,786,273
Identification of biomarkers using single cell technology that inform on optimal duration of immunotherapy treatment in melanoma
CIHR · 2022 · Co-investigator
$1,422,900
Anti-parathyroid hormone-related protein (PTHrP) monoclonal antibodies against metastatic cancer
CIHR · 2022 · Principal investigator
$665,550

All 9 grants and awards

31 publications.

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

Othus M, Truong TG, Sharon E, Kendra K, Grossmann K, Buchbinder E, Khushalani NI, Eroglu Z, Chandra S, Doolittle GC, Kirkwood JM, Ikeguchi A, Mihalcioiu C, Cowey CL, Reddy SA, Johnson DB, Taylor M, Sondak VK, Ribas A, Patel SP

JCO oncology practice2026

DOI: 10.1200/op-25-01413 PMID: 42335437

Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer.

Diop K, Benlaïfaoui M, Hunter S, Méndez-Salazar EO, Hakozaki T, Richard C, Prifti DK, Kourtian S, Proulx-Rocray F, Naimi S, Ponce M, Messaoudene M, Cauchois F, Belkaid W, Bataille V, Lee K, Mihalcioiu C, Watson IR, Elkrief A, Routy B

Microbiome2026

DOI: 10.1186/s40168-026-02419-4 PMID: 42083059

Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.

Duttagupta S, Messaoudene M, Hunter S, Desilets A, Jamal R, Mihalcioiu C, Belkaid W, Marcoux N, Fidelle M, Suissa D, Ponce M, Geiger M, Malo J, Piccinno G, Punčochář M, Filin A, Heidrich V, Rusu D, Mbaye B, Durand S, Ben Aissa I, Puller V, de Lahondès R, Blais N, Tehfe M, Owen S, Bélanger K, Parvathy SN, Shieh B, Raphael J, Lenehan J, Breadner D, Rothenstein J, Rozza N, Maillou J, Nili S, Prifti DK, Pinto F, Armanini F, Kim-Schulze S, Marron TU, Kroemer G, Derosa L, Zitvogel L, Silverman M, Segata N, Maleki Vareki S, Routy B, Elkrief A

Nature medicine2026

DOI: 10.1038/s41591-025-04186-5 PMID: 41606121

The epiMelanoma test enables plasma-based detection of melanoma and prediction of immunotherapy response.

Dumas O, Rozza N, Cheishvili D, Luk S, Sin STK, Khassenova A, Kremer R, Szyf M, Mihalcioiu C, Rabbani SA

Scientific reports2025

DOI: 10.1038/s41598-025-13952-x PMID: 40841414

The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma.

Berry D, Moldoveanu D, Rajkumar S, Lajoie M, Lin T, Tchelougou D, Sakthivel S, Sharon I, Bernard A, Pelletier S, Ripstein Y, Spatz A, Miller WH, Jamal R, Lapointe R, Mes-Masson AM, Petrecca K, Meguerditchian AN, Richardson K, Wang B, Chergui M, Guiot MC, Watters K, Stagg J, Schmeing TM, Rodier F, Turcotte S, Mihalcioiu C, Meterissian S, Watson IR

Cell reports2025

DOI: 10.1016/j.celrep.2025.115365 PMID: 40023845

A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.

Yaeger R, McKean MA, Haq R, Beck JT, Taylor MH, Cohen JE, Bowles DW, Gadgeel SM, Mihalcioiu C, Papadopoulos KP, Diamond EL, Sturtz KB, Feng G, Drescher SK, Reddy MB, Sengupta B, Maity AK, Brown SA, Singh A, Brown EN, Baer BR, Wong J, Mou TC, Wu WI, Kahn DR, Gadal S, Rosen N, Gaudino JJ, Lee PA, Hartley DP, Rothenberg SM

Cancer discovery2024

DOI: 10.1158/2159-8290.cd-24-0024 PMID: 38691346

Decreased progenitor TCF1 + T-cells correlate with COVID-19 disease severity.

Tu TH, Grunbaum A, Santinon F, Kazanova A, Rozza N, Kremer R, Mihalcioiu C, Rudd CE

Communications biology2024

DOI: 10.1038/s42003-024-05922-2 PMID: 38702425

The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers.

Aguilar-Mahecha A, Alirezaie N, Lafleur J, Bareke E, Przybytkowski E, Lan C, Cavallone L, Salem M, Pelmus M, Aleynikova O, Greenwood C, Lovato A, Ferrario C, Boileau JF, Mihalcioiu C, Roy JA, Marcus E, Discepola F, Majewski J, Basik M

Genes2023

DOI: 10.3390/genes15010027 PMID: 38254917

Improved platform for breast cancer circulating tumor cell enrichment and characterization with next-generation sequencing technology.

Mihalcioiu C, Li J, Badescu D, Camirand A, Kremer N, Bertos N, Omeroglu A, Sebag M, Di Battista J, Park M, Ragoussis J, Kremer R

American journal of cancer research2023First author

PMID: 36777514

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.

Arance A, de la Cruz-Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, Berrocal A, Márquez-Rodas I, Spreafico A, Atkinson V, Costa Svedman F, Mant A, Khattak MA, Mihalcioiu C, Jang S, Cowey CL, Smith AD, Hawk N, Chen K, Diede SJ, Krepler C, Long GV

Journal of clinical oncology : official journal of the American Society of Clinical Oncology2023

DOI: 10.1200/jco.22.00221 PMID: 35867951

Something wrong or missing on this profile? Suggest a correction

Catalin Mihalcioiu

Research

Latest papers

Latest funding

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

Metagenomics and culturomics reveal the dual role of the gut microbiome in the development of immune-related toxicities and the efficacy of immune checkpoint inhibitors in cancer.

Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.

The epiMelanoma test enables plasma-based detection of melanoma and prediction of immunotherapy response.

The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma.

A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.

Decreased progenitor TCF1&#x2009;+&#x2009;T-cells correlate with COVID-19 disease severity.

The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers.

Improved platform for breast cancer circulating tumor cell enrichment and characterization with next-generation sequencing technology.

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.

Multidimensional separation isolation and characterization of circulating tumour cells

Frequent collaborators

Richard Kremer

Arielle Elkrief

Mark Basik

Jacek Majewski

Kevin Petrecca

ATILLA Omeroglu

Kevin Petrecca

Morag Park

Bertrand Routy

Sarkis Meterissian

Moshe Szyf

Celia Greenwood

Anna Spreafico

Marie Hudson

Francis Rodier

Stephen Welch

Moulay Alaoui-Jamali

Thierry Muanza

Michael Silverman

Simon Gravel

Bertrand Jean-Claude

Michael Sebag

Gerald Batist

Wilson Miller

Gerald Batist

Decreased progenitor TCF1 + T-cells correlate with COVID-19 disease severity.